Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT01869309

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT01869309
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01869309. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
Acronym
HEIGHTEN
Intervention (Drug)
Prasugrel
Intervention (Drug)
Ticagrelor
Lead sponsor
LifeBridge Health (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01869309
Content hash
3aaa2aa23f8ff49f9690f55d137d9ae65fbd651b5fe960413be1972b59256c0c